http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Yi-min Ge (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Yi Luan,Wenbin Zhang,Min Wang,Pei Zhang,Zhimin Xue,Guosheng Fu,Junbo Ge 한국유전학회 2016 Genes & Genomics Vol.38 No.9
The methylenetetrahydrofolate reductase (MTH FR) gene variant 677C?T is considered a risk factor for myocardial infarction (MI) in Caucasians, but it remains unclear whether this applies to Chinese or other Asian populations. A total of 551 controls and 304 age-matched Chinese MI patients were recruited. MTHFR genotypes were determined. A subsequent meta-analysis was performed to determine the association between MTHFR and MI in Asia. Conventional risk factors such as hypertension, diabetes mellitus and low-density lipoprotein exhibited no significant differences between the two groups. Genotype frequencies among cases and controls were compatible with Hardy– Weinberg equilibrium. The frequencies of CC, CT and TT genotypes were 28, 46 and 26 % for patients with MI and 31, 52 and 17 % for the matched control group (p = 0.006). T-allele frequency in MI patients was higher than in controls (49 vs. 43 %, odds ratio = 0.785, 95 % confidence interval = 0.644–0.958, p = 0.017). A total of 16 studies including ours were identified, involving 4053 patients and 6791 controls. A recessive genotype model of MTHFR 677C?T polymorphism, but not a dominant genotypemodel, was significantly associated with greater MIrisk in Asians. MI risk increased 48, 37 and 47 % for the TT homozygote compared with the CC wild type, CT heterozygote and the combination of CT and CC. Thus, we conclude that the MTHFR gene variant 677C?T is a risk factor for MI in the Chinese population and the TT genotype is associated with a significant increase in MI risk in Asia.
-
A Novel Hybrid Control Strategy for an Underactuated 3-D Biped with Asymmetric Structure
Hai-hui Yuan,Yi-min Ge,Chun-biao Gan 대한전기학회 2019 Journal of Electrical Engineering & Technology Vol.14 No.3
In reality, due to the manufacturing error or the component loss in the service process, the structural parameters of bipedal robots may exhibit asymmetry. In this work, we consider the stable walking of an underactuated 3-D bipedal robot with asymmetric structure, and a novel hybrid control strategy is proposed. The control strategy consists of a continous heuristic motion controller, which asymptotically drive the state of the robot to the zero dynamics manifold, and an event-based feedback controller that renders the hybrid zero dynamics locally asymptotically stable. The heuristic motion controller uses heuristic state variables as controlled variables rather than simply the actuated variables, and the controller parameters of the event-based feedback controller are designed in an analytical method rather than relying on the left–right symmetry property. The eff ectiveness of the presented control strategy is illustrated by a numerical simulation example.
-
( Hye Young Kim ),( Nam Joon Yi ),( Ju Yeun Lee ),( Joo Hyun Kim ),( Mi Ra Moon ),( Jae Hong Jeong ),( Jeong Moo Lee ),( Tae Suk You ),( Suk Won Suh ),( Min Su Park ),( Young Rok Choi ),( Ge Un Hong ) 대한간학회 2014 Clinical and Molecular Hepatology(대한간학회지) Vol.20 No.3
Background/Aims: The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associated with the conventional fixed dose of 2-3 g/day. We aimed to determine the pharmacokinetics of a reduced dose of MMF and to validate its feasibility in combination with tacrolimus in living-donor liver transplantation (LDLT). Methods: Two sequential studies were performed in adult LDLT between October 2009 and 2011. First, we performed a prospective pharmacokinetic study in 15 recipients. We measured the area under the curve from 0 to 12 hours (AUC0-12) for mycophenolic acid at postoperative days 7 and 14, and we performeda protocol biopsy before discharge. Second, among 215 recipients, we reviewed 74 patients who were initially administered a reduced dose of MMF (1.0 g/day) with tacrolimus (trough, 8-12 ng/mL during the first month, and 5-8 ng/mL thereafter), with a 1-year follow-up. We performed protocol biopsies at 2 weeks and 1 year post-LDLT. Results: In the first part of study, AUC0-12 was less than 30 mgh/L in 93.3% of cases. In the second,validating study, 41.9% of the recipients needed dose reduction or cessation due to side effects within the first year after LDLT. At 12 months post-LDLT, 17.6% of the recipients were administered a lower dose of MMF (0.5 g/day), and 16.2% needed permanent cessation due to side effects. The 1- and 12 month rejection-free survival rates were 98.6% and 97.3%, respectively. Conclusions: A reduced dose of MMF was associated with low blood levels compared to the existing recommended therapeutic range. However, reducing the dose of MMF combined with a low level of tacrolimus was feasible clinically, with an excellent short-term outcome in LDLT. (Clin Mol Hepatol 2014;20:291-299)
KCI
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
